Cargando…

Machine learning and synthetic outcome estimation for individualised antimicrobial cessation

The decision on when it is appropriate to stop antimicrobial treatment in an individual patient is complex and under-researched. Ceasing too early can drive treatment failure, while excessive treatment risks adverse events. Under- and over-treatment can promote the development of antimicrobial resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolton, William J., Rawson, Timothy M., Hernandez, Bernard, Wilson, Richard, Antcliffe, David, Georgiou, Pantelis, Holmes, Alison H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719971/
https://www.ncbi.nlm.nih.gov/pubmed/36479189
http://dx.doi.org/10.3389/fdgth.2022.997219
_version_ 1784843446834429952
author Bolton, William J.
Rawson, Timothy M.
Hernandez, Bernard
Wilson, Richard
Antcliffe, David
Georgiou, Pantelis
Holmes, Alison H.
author_facet Bolton, William J.
Rawson, Timothy M.
Hernandez, Bernard
Wilson, Richard
Antcliffe, David
Georgiou, Pantelis
Holmes, Alison H.
author_sort Bolton, William J.
collection PubMed
description The decision on when it is appropriate to stop antimicrobial treatment in an individual patient is complex and under-researched. Ceasing too early can drive treatment failure, while excessive treatment risks adverse events. Under- and over-treatment can promote the development of antimicrobial resistance (AMR). We extracted routinely collected electronic health record data from the MIMIC-IV database for 18,988 patients (22,845 unique stays) who received intravenous antibiotic treatment during an intensive care unit (ICU) admission. A model was developed that utilises a recurrent neural network autoencoder and a synthetic control-based approach to estimate patients’ ICU length of stay (LOS) and mortality outcomes for any given day, under the alternative scenarios of if they were to stop vs. continue antibiotic treatment. Control days where our model should reproduce labels demonstrated minimal difference for both stopping and continuing scenarios indicating estimations are reliable (LOS results of 0.24 and 0.42 days mean delta, 1.93 and 3.76 root mean squared error, respectively). Meanwhile, impact days where we assess the potential effect of the unobserved scenario showed that stopping antibiotic therapy earlier had a statistically significant shorter LOS (mean reduction 2.71 days, [Formula: see text]-value <0.01). No impact on mortality was observed. In summary, we have developed a model to reliably estimate patient outcomes under the contrasting scenarios of stopping or continuing antibiotic treatment. Retrospective results are in line with previous clinical studies that demonstrate shorter antibiotic treatment durations are often non-inferior. With additional development into a clinical decision support system, this could be used to support individualised antimicrobial cessation decision-making, reduce the excessive use of antibiotics, and address the problem of AMR.
format Online
Article
Text
id pubmed-9719971
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97199712022-12-06 Machine learning and synthetic outcome estimation for individualised antimicrobial cessation Bolton, William J. Rawson, Timothy M. Hernandez, Bernard Wilson, Richard Antcliffe, David Georgiou, Pantelis Holmes, Alison H. Front Digit Health Digital Health The decision on when it is appropriate to stop antimicrobial treatment in an individual patient is complex and under-researched. Ceasing too early can drive treatment failure, while excessive treatment risks adverse events. Under- and over-treatment can promote the development of antimicrobial resistance (AMR). We extracted routinely collected electronic health record data from the MIMIC-IV database for 18,988 patients (22,845 unique stays) who received intravenous antibiotic treatment during an intensive care unit (ICU) admission. A model was developed that utilises a recurrent neural network autoencoder and a synthetic control-based approach to estimate patients’ ICU length of stay (LOS) and mortality outcomes for any given day, under the alternative scenarios of if they were to stop vs. continue antibiotic treatment. Control days where our model should reproduce labels demonstrated minimal difference for both stopping and continuing scenarios indicating estimations are reliable (LOS results of 0.24 and 0.42 days mean delta, 1.93 and 3.76 root mean squared error, respectively). Meanwhile, impact days where we assess the potential effect of the unobserved scenario showed that stopping antibiotic therapy earlier had a statistically significant shorter LOS (mean reduction 2.71 days, [Formula: see text]-value <0.01). No impact on mortality was observed. In summary, we have developed a model to reliably estimate patient outcomes under the contrasting scenarios of stopping or continuing antibiotic treatment. Retrospective results are in line with previous clinical studies that demonstrate shorter antibiotic treatment durations are often non-inferior. With additional development into a clinical decision support system, this could be used to support individualised antimicrobial cessation decision-making, reduce the excessive use of antibiotics, and address the problem of AMR. Frontiers Media S.A. 2022-11-21 /pmc/articles/PMC9719971/ /pubmed/36479189 http://dx.doi.org/10.3389/fdgth.2022.997219 Text en © 2022 Bolton, Rawson, Hernandez, Wilson, Antcliffe, Georgiou and Holmes. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Digital Health
Bolton, William J.
Rawson, Timothy M.
Hernandez, Bernard
Wilson, Richard
Antcliffe, David
Georgiou, Pantelis
Holmes, Alison H.
Machine learning and synthetic outcome estimation for individualised antimicrobial cessation
title Machine learning and synthetic outcome estimation for individualised antimicrobial cessation
title_full Machine learning and synthetic outcome estimation for individualised antimicrobial cessation
title_fullStr Machine learning and synthetic outcome estimation for individualised antimicrobial cessation
title_full_unstemmed Machine learning and synthetic outcome estimation for individualised antimicrobial cessation
title_short Machine learning and synthetic outcome estimation for individualised antimicrobial cessation
title_sort machine learning and synthetic outcome estimation for individualised antimicrobial cessation
topic Digital Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719971/
https://www.ncbi.nlm.nih.gov/pubmed/36479189
http://dx.doi.org/10.3389/fdgth.2022.997219
work_keys_str_mv AT boltonwilliamj machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation
AT rawsontimothym machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation
AT hernandezbernard machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation
AT wilsonrichard machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation
AT antcliffedavid machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation
AT georgioupantelis machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation
AT holmesalisonh machinelearningandsyntheticoutcomeestimationforindividualisedantimicrobialcessation